Osteoclasts are responsible for the bone erosion associated with rheumatoid arthritis (RA). The upregulation of the chemokines CCL19 and CCL21 and their receptor CCR7 has been linked to RA pathogenesis. The purpose of this study was to evaluate the effects of CCL19 and CCL21 on osteoclasts and to reveal their underlying mechanisms. The expression of CCL19, CCL21 and CCR7 was higher in RA patients than in osteoarthritis patients. In differentiating osteoclasts, tumor necrosis factor-α, interleukin-1β and lipopolysaccharide stimulated CCR7 expression. CCL19 and CCL21 promoted osteoclast migration and resorption activity. These effects were dependent on the presence of CCR7 and abolished by the inhibition of the Rho signaling pathway. CCL19 and CCL21 promoted bone resorption by osteoclasts in an in vivo mice calvarial model. These findings demonstrate for the first time that CCL19, CCL21 and CCR7 play important roles in bone destruction by increasing osteoclast migration and resorption activity. This study also suggests that the interaction of CCL19 and CCL21 with CCR7 is an effective strategic focus in developing therapeutics for alleviating inflammatory bone destruction.
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation and bone destruction in joint areas. Bone destruction by osteoclasts becomes more severe as the disease progresses. 1 Osteoclast precursors (monocytes and macrophages) and osteoclasts are recruited to the inflamed synovium and are activated to evoke the erosion of subchondral bone. 2 Therefore, the migration of these cells to joint areas is an important step in RA pathogenesis. Several factors, such as CXCL12 (SDF-1), TGF-β and CX 3 CL1 (fractalkine), have been reported to promote osteoclast migration. [3] [4] [5] These factors enhance osteoclast recruitment to the bone surface and in some cases augment osteoclastogenesis directly or indirectly.
The chemokines CCL19 and CCL21 both recruit various types of cells, such as leukocytes, immune cells and certain tumor cells. [6] [7] [8] [9] [10] [11] In particular, both CCL19 and CCL21 promote the in vitro migration and maturation of dendritic cells, which share their precursors with osteoclasts. 12, 13 In mice, the genetic deletion of CCR7, the receptor shared by CCL19 and CCL21, led to a loss of dendritic cell migration ability. 14 In addition, the localization of macrophages in the marginal zone of the spleen is regulated by CCL19 and CCL21. 15 These reports suggest that CCL19 and CCL21 are involved in the migration and/or activation of osteoclasts.
CCR7 is a G-protein-linked cell-surface receptor that is expressed in hematopoietic cells, such as T cells, B cells, dendritic cells, macrophages and neutrophils. 16 The common function of CCR7 in these cells is the promotion of migration. A recent study reported that via CCR7, CCL19 stimulates the migration of bone marrow mesenchymal stem cells that can differentiate into osteoblasts. 17 However, the function of CCR7 in osteoclasts has not yet been investigated.
Recent studies have shown that the expression of CCL19 and CCL21 is elevated in the synovial tissues of RA patients. 18 An investigation revealed that the levels of CCL19 in plasma and the CCR7 expression on monocytes increased in early RA conditions; these were decreased by 1 year and 5 years of RA therapy. 19 These results suggest that CCL19 and CCL21 and their receptor CCR7 might be crucial for RA pathophysiology.
The intracellular signaling pathways triggered by CCR7 have not been well described. However, the small GTPase protein RhoA is suggested to be responsible for the CCR7-dependent migration of monocytes. 20 In addition, CCR7-mediated chemotaxis and the polarization of T cells were shown to require Rho kinase (ROCK), a downstream target of RhoA. 21 RhoA and other small GTPase family proteins are also reported to stimulate cytoskeleton rearrangement, migration, and the bone resorption activity of osteoclasts. [22] [23] [24] Therefore, CCR7 and its ligands may play important roles in the migration of osteoclasts via RhoA and ROCK.
In this study, we investigated the effects of CCL19 and CCL21 on osteoclast migration and bone resorption. The underlying mechanisms by which these chemokines function in osteoclasts were also explored.
MATERIALS AND METHODS Reagents
Recombinant CCL19 and CCL21 were obtained from Prospec (East Brunswick, NJ, USA). The primary antibodies for CCR7, phosphoSer19 MLC (p-MLC) and β-actin were purchased from Abcam (Cambridge, Cambridgeshire, UK), Millipore (Temecula, CA, USA) and Sigma (St Louis, MO, USA), respectively. The antimouse and antirabbit secondary antibodies and Rho inhibitors simvastatin and Y27632 were obtained from Sigma. The Rho Activation Assay kits were bought from Millipore. CCR7 small interference RNA (siRNA) was provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA). The siRNA transfection reagent HiPerFect was obtained from Qiagen (Valencia, CA, USA).
Osteoclast differentiation
Murine osteoclast differentiation culturing was performed as previously described. 25 Bone marrow cells were flushed from the femurs and tibias of 5-week-old female ICR mice. Harvested cells were incubated in culture dishes for 1 day, and nonadherent cells were incubated further in Petri dishes with M-CSF (30 ng ml − 1 ). After 3 days of culture, the adherent cells were collected and considered to be bone marrow-derived macrophages (BMMs). The BMMs were cultured in α-MEM containing 10% FBS with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) for osteoclast differentiation.
Enzyme-linked immunosorbent assay
The CCL19 and CCL21 levels were measured using CCL19 and CCL21 enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). To prepare the ELISA plates, the capture antibodies were diluted in PBS to a working concentration. A volume of 100 μl of the antibodies was added to 96-well plates, and the plates were incubated overnight at room temperature. The wells were aspirated and washed with wash buffer three times. The plates were blocked with 300 μl of diluent reagent, incubated for 1 h at room temperature, and washed again. A volume of 100 μl of standards or samples diluted in diluent reagent was prepared. The samples were added to the wells and incubated for 2 h at room temperature. The plates were washed with wash buffer. After adding 100 μl of the detection antibodies to the wells, the plates were incubated for 2 h at room temperature and washed with wash buffer. A volume of 100 μl of streptavidin-HRP reagent was added to the wells, and the plates were incubated for 20 min at room temperature without direct light. After washing three times, 100 μl of substrate solution was added to the wells, and the plates were incubated for 20 min at room temperature without direct light. Stop solution (50 μl) was added, and the optical density of the wells was measured immediately at 450 nm. The sera and synovial fluids were from osteoarthritis (OA) (n = 15) and RA (n = 24) patients. Patient samples were handled following the guidelines of the Institutional Review Board of Seoul National University Hospital.
Real-time PCR
The total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed using SuperScript II reverse transcriptase (Invitrogen). Complementary DNA was amplified with primers using a real-time PCR instrument (AB7500, Life Technologies, Carlsbad, CA, USA). The expression of mRNA was normalized to the 18S rRNA gene.
Western blot analysis
The cells were lysed with 6 × boiling SDS sample buffer. The protein samples were quantified using protein assay kits (Bio-Rad, Hercules, CA, USA), and 30 μg were loaded onto polyacrylamide gels. The separated proteins were transferred to nitrocellulose membranes. The membranes were blocked in 5% skim milk followed by incubation with the primary antibody (1:1000) overnight at 4°C and the secondary antibody (1:10 000) for 1 h at room temperature. Immunoreactive bands were detected with chemiluminescence reagents.
TRAP staining
BMMs were seeded at 2 × 10 4 cells per well and cultured under differentiation conditions. After 4 days, the cells were fixed with 3.7% formaldehyde for 15 min and permeabilized with 0.1% Triton X-100 for 1 min. The cells were treated with tartrate-resistant acid phosphatase (TRAP) staining solution (Sigma) following the manufacturer's protocol. After 15 min, the TRAP-positive cells were counted under an Olympus 23 light microscope (Olympus, Tokyo, Japan).
Flow cytometry
BMMs were incubated with lipopolysaccharide (LPS) (5 ng ml − 1 ) for 1 day. The cells were collected with a scraper, washed by centrifugation at 400 g for 5 min for a total of three times in PBS containing 2% FBS, and incubated with the CCR7 antibody (1:40) for 30 min at 4°C. After washing three more times, the cells were treated with a secondary antibody (1:1000) (Invitrogen) for 20 min and washed three times. Immediately, the cells were analyzed with a FACSCalibur flow cytometer (BD Science, Franklin Lakes, NJ, USA).
Small interference RNA transfection
BMMs (2 × 10 5 ) were seeded in six-well culture plates and incubated for 24 h. Mixtures of 20 nmole siRNA oligonucleotides and the HiPerFect reagent were added to the wells. After 24 h, the medium was replaced with fresh medium, and the cells were cultured.
Cell migration assays
The BMM migration assays used transwell migration assay kits (Corning, Corning, NY, USA). BMMs (1 × 10 5 ) were seeded in the upper chambers, and CCL19 or CCL21 was added to the lower chambers. For Rho inhibitor experiments, BMMs were pretreated with simvastatin or Y27632 for 1 h. After incubating for 18 h at 37°C, the cells were fixed in 3.7% formaldehyde for 30 min and stained with crystal violet for 10 min. For the osteoclast migration experiments, Oris Cell Migration Assay kits (Platypus Technologies, Madison, WI, USA) were used. BMMs (1 × 10 5 ) were seeded in assay plates with stoppers and cultured in the presence of RANKL (100 ng ml − 1 ) and M-CSF (30 ng ml − 1 ). After 2 days, the stoppers were removed to allow the cells to migrate into the detection zone. After 16 h at 37°C, the cells were fixed with 3.7% formaldehyde and stained with crystal violet.
Rho pull-down assays BMM cells (2 × 10 6 ) were cultured in 100-mm culture dishes and stimulated with CCL19 or CCL21 for the indicated times. The cells were harvested in lysis buffer (125 mM HEPES, pH 7.5, 570 mM NaCl, 5% lgepal CA-630, 50 mM MgCl 2 , 5 mM EDTA and 10% glycerol) from the Rho Activation Assay kits. Protein samples were obtained from the cell extracts by centrifugation and incubated with 20 μl of the Rho Assay Reagent slurry (beads) for 1 h at 4°C. The beads were washed three times in lysis buffer, and reducing sample buffer was added. After boiling, the samples were used for western blots.
Resorption assays
BMMs were seeded on calcium phosphate-coated plates and cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) in the presence or absence of CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ) for 6 days. After washing out the cells with distilled water, the plates were treated with a 5% silver nitrate solution for 1 h, washed with distilled water and treated with a sodium carbonate-formaldehyde solution (5% Na 2 CO 3 , 9.25% formaldehyde) for 2 min. Alternatively, BMMs were cultured on dentin slices with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) in the absence or presence of CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). After 6 days, the dentin slice surfaces were analyzed by confocal microscopy. The resorption pit areas were quantified after staining the dentin slices with Trypan Blue.
Confocal fluorescence microscopy
BMMs were cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) with or without CCL19 (10 ng ml − 1 ) and CCL21 (10 ng ml − 1 ) for 6 days. The cells were fixed with 3.7% formaldehyde for 30 min, blocked in 1% bovine serum albumin for 2 h, and treated with phalloidin rhodamine for 2 h. The cells were washed with PBS containing 1% BSA three times after each step. The cell nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Zeiss LSM 7 PASCAL laser-scanning microscope (Carl Zeiss Microimaging, GmbH, Goettingen, Germany) was used to observe the actin rings.
In vivo mouse calvarial assay
Collagen sponges were soaked in 2 μg of CCL19, CCL21 or PBS and transplanted into 5-week-old ICR mouse calvariae subcutaneously. For LPS injection experiments, LPS (1 mg kg − 1 ) was injected into 5-week-old ICR mice intraperitoneally twice at 4-day intervals with the first injection 1 day before CCL19 transplantation. The mice were killed 7 days after transplantation. The calvariae were collected, fixed in 4% paraformaldehyde for 1 day and analyzed by micro-computed tomography (μ-CT) using a SkyScan 1072 instrument (SkyScan, Aartselaar, Belgium). The calvariae from the CCL19-or CCL21-treated group and the control group were fixed in 4% paraformaldehyde for 18 h and decalcified with 12% EDTA for 4 weeks. The calvariae were dehydrated with 70-100% ethanol, cleared with chloroform and embedded in paraffin. The paraffin blocks were sectioned at 5 μm thickness. Tissue sections were placed on slide glasses and stained with TRAP solution. Histomorphometric analyses were performed with the Osteomeasure program (OsteoMetrics, GA, USA). All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Seoul National University.
Statistical analysis
All experiments, except the human sample analyses and in vivo calvarial bone resorption assays, were performed at least three times. The quantitative data were expressed as the mean ± s.d. P-values were determined by a two-tailed Student's t-test or a one-way analysis of variance followed by Tukey's test. P-values o0.05 were considered significant.
RESULTS

Expression of CCL19, CCL21 and CCR7 is elevated in RA patients
In the course of screening the chemokines differentially expressed in RA specimens compared to OA samples, we found that the protein levels of CCL19 and CCL21 were higher in the RA samples. The ELISA analyses showed a significantly higher level of those chemokines both in the synovial fluids and in the sera (Figure 1) . Our results agree with previous reports from an immunostaining study of the synovial tissues and an ELISA study with the synovial fluids from RA patients. 18 We also scrutinized microarray data deposited in the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/gds) to gain further evidence of the link between CCL19 and CCL21 and RA. GEO data GPL91:GSE1919 showed that the mRNA of CCL19, but not CCL21, was more abundant in the synovial tissues of RA patients than in those of normal donors (Supplementary Figure 1) . Although statistical significance was lacking, perhaps because of the small number of samples, there were higher levels of CCL19 and CCL21 mRNA in RA synovial tissues than in OA tissues (Supplementary Figure 1) . Figure 1 Upregulation of CCL19 and CCL21 in RA patients. The levels of CCL19 and CCL21 in the synovial fluids and sera from RA (n = 24) and OA (n = 15) patients. The CCL19 and CCL21 levels were measured using human ELISA kits. OA, osteoarthritis; RA, rheumatoid arthritis.
CCR7 expression increased in response to inflammatory stimuli in osteoclasts RA is a chronic inflammatory condition in which tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are constitutively produced. These inflammatory cytokines and LPS were shown to increase the CCL19 and CCL21 mRNA in synovial fibroblasts. 18 As these inflammatory stimuli have a potent impact on RANKL-induced osteoclast differentiation and subsequent bone erosion in the RA synovium, we next investigated whether these factors affected the expression of CCL19 and CCL21 and their receptor CCR7 during osteoclast differentiation from BMMs, the primacy cells of osteoclast precursors. The mRNA levels of CCL19 and CCL21 were undetectable during osteoclastic differentiation in the presence and absence of TNF-α, IL-1β or LPS (data not shown).
In contrast to the expression pattern of CCL19 and CCL21, the presence of CCR7 mRNA was clearly detected in BMMs. During RANKL-induced osteoclast differentiation in the absence of inflammatory stimulus, the CCR7 mRNA levels did not change (Figures 2a-c) . The addition of TNF-α or IL-1β to cultures containing RANKL increased the CCR7 mRNA by more than four times that of the control (Figures 2a and b) , and the addition of LPS increased the CCR7 mRNA by~15 times that of the control (Figure 2c ). Western blotting analyses demonstrated an elevated level of CCR7 protein in the LPS-stimulated BMMs at 12 and 24 h (Figure 2d ). Furthermore, the surface CCR7 level measured at 24 h after LPS stimulation by flow cytometry was higher than that of the PBS-treated group. The addition of LPS increased the surface CCR7 more than 10 times that of the control (Figure 2e ). TNF-α and IL-1β also increased the cell surface CCR7 weakly (data not shown). Collectively, TNF-α, IL-1β and LPS increased the expression of CCR7 at the mRNA and protein levels in osteoclast precursors and differentiating cells.
CCL19 and CCL21 do not affect osteoclast differentiation
We next evaluated the effect of CCL19 and CCL21 on osteoclast differentiation. Precursor BMM cells were cultured with CCL19 in osteoclastogenic medium containing RANKL and subjected to TRAP staining. There was no difference in the number of TRAP-positive multinuclear cells (osteoclasts) between the cytokine-treated group and the untreated group (Figure 3a) . Furthermore, no difference was observed between the two groups in terms of the expression of the differentiation marker genes c-Fos, NFATc1 and DC-STAMP (Figure 3b ). CCL21 also did not affect the generation of TRAP-positive osteoclasts or the expression of marker genes (Figures 3c and d) . Neither CCL19 nor CCL21 induced osteoclast differentiation in the absence of RANKL (data not shown). Therefore, CCL19 and CCL21 did not exert any effect on the formation of osteoclasts. CCL19 and CCL21 enhance osteoclast migration As CCL19 and CCL21 are chemokines that stimulate immune cell migration, we explored the possibility that these chemokines regulate osteoclast migration. We assessed the effect of CCL19 and CCL21 on BMM migration using a transwell system. CCL19 and CCL21 increased the migration of BMMs (Figure 4a ). The migration ability of differentiating prefusion osteoclasts was evaluated using the Oris migration assay system. At 16 h after removing the stopper that had blocked cell migration, the stopper areas were filled with more cells in the group treated with CCL19 or CCL21 than the group treated with control vehicle (Figure 4b) .
We next investigated whether CCR7 mediated the migration-promoting effect of CCL19 and CCL21. The expression of CCR7 was suppressed by gene knockdown using siRNA oligonucleotides. The reduction in the CCR7 mRNA and protein was verified by real-time PCR and western blots, respectively (Figure 4c ). BMMs with CCR7 knocked down failed to increase migration in response to CCL19 or CCL21 (Figure 4d ). These results indicated that CCL19 and CCL21 stimulated the migration of osteoclast precursor cells and differentiating osteoclasts via a CCR7-dependent mechanism.
CCL19 and CCL21 increase osteoclast resorption activity
We next examined whether CCL19 and CCL21 might have an impact on the resorption function of osteoclasts. BMMs were cultured on calcium phosphate-coated plates in osteoclastogenic medium containing RANKL with or without CCL19 or CCL21. Cells treated with CCL19 or CCL21 generated a greater area of calcium phosphate dissolution than cells not treated BMMs were plated in Oris migration assay plates. The cells were incubated with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ). After 2 days, the stoppers were removed, and the cells were washed twice with fresh medium. The cells were incubated with or without CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). After 16 h, the cells were fixed and stained with crystal violet. The stopper areas occupied with cells were quantified. (c) BMMs were transfected with control or CCR7 siRNA using Hiperfect. The levels of CCR7 mRNA and protein were assessed by PCR and western blots, respectively. (d) BMMs transfected with either CCR7 or control siRNA were loaded into the upper chambers of a transwell plate. CCL19 or CCL21 was added to the lower chambers. After 16 h, the cells were fixed and stained with crystal violet. Migrated BMMs were counted. BMM, bone marrow-derived macrophages; siRNA, small interference RNA.
with one of these chemokines (Figure 5a ). The resorption activity of osteoclasts was also tested with dentine slices. Confocal microscopic analyses revealed that CCL19 and CCL21 increased the number and depth of the resorption pits on dentin surfaces (Figure 5b, top three panels) . Quantitative measurement of the dentine slices after staining with Trypan Blue showed increased resorbed area with CCL19 or CCL21 treatment (Figure 5b, bottom panel) . Cytoskeletal rearrangements and actin ring formation are a prerequisite for bone resorption by osteoclasts. To visualize the actin ring Figure 5 CCL19 and CCL21 enhance osteoclast bone resorption activity. (a) BMMs were placed on calcium phosphate-coated plates and cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ), along with CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). After 6 days, calcium phosphate was stained with von Kossa reagents, and the resorbed area was quantified. (b) BMMs were placed on dentin slices and cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ), along with CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). After 6 days, the dentin slice surfaces were analyzed by confocal microscopy. The dentin slices were stained with trypan blue, and the resorption pit areas were quantified. (c) BMMs were cultured on cover glasses and cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) in the presence of CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). After 6 days, the cells were fixed and incubated with rhodamine phalloidin. The actin ring density was quantified by confocal microscopy. BMM, bone marrow-derived macrophages. Figure 6 LPS upregulates the CCL19-and CCL21-induced osteoclast migration and bone resorption activity. (a) BMMs were pretreated with LPS (5 ng ml − 1 ) or control vehicle for 12 h and seeded in the upper chambers of transwell plates. CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ) was added to the lower chambers. After 16 h, the cells were fixed and stained with crystal violet. The migrated cells were counted. (b) BMMs were seeded on calcium phosphate-coated plates and cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) for 4 days. The cells were pretreated with LPS (5 ng ml − 1 ) or vehicle. After 1 day, the cells were treated with CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). After 2 days, calcium phosphate was stained with von Kossa reagents, and the resorbed area was quantified. (c) BMMs were placed on cover glasses and cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) for 4 days. The cells were treated with CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ) after 1 day of pretreatment with LPS (5 ng ml − 1 ) or control vehicle. At day 6 of the culture, the cells were fixed and incubated with rhodamine phalloidin. The actin ring density was quantified by confocal microscopy. BMM, bone marrow-derived macrophages; LPS, lipopolysaccharide.
formation of osteoclasts, the cells were stained with rhodamine-conjugated phalloidin and subjected to confocal microscopy. Osteoclasts treated with CCL19 or CCL21 showed more dense and prominent actin rings compared with osteoclasts generated in the absence of CCL19 or CCL21 (Figure 5c ).
LPS enhances CCL19 and CCL21 stimulation of osteoclast migration and bone resorption activity We next evaluated the effects of CCR7 upregulation on the stimulatory function of CCL19 and CCL21 on osteoclast migration, bone resorption and actin ring formation. To this end, the cells were pretreated with LPS to induce CCR7 expression before stimulation with CCL19 or CCL21. LPS pretreatment increased the migration of BMMs induced by CCL19 or CCL21 in the transwell assays (Figure 6a ). In addition, LPS augmented the positive effect of CCL19 and CCL21 on the resorption activity of osteoclasts on calcium phosphate-coated plates (Figure 6b ). Consistently, osteoclasts treated with LPS generated more prominent actin rings than the cells in the control group (Figure 6c ). These data suggested that LPS, probably via CCR7 upregulation, further increases osteoclast migration, bone resorption activity and actin ring formation in response to CCL19 or CCL21.
CCL19 and CCL21 stimulate osteoclasts via the Rho-ROCK signaling pathway Active RhoA GTPase is crucial for cell migration, and CCR7 activates RhoA GTPase in monocytes. 20 Therefore, we investigated the involvement of RhoA in the CCL19 and CCL21 stimulation of osteoclasts. In pulldown experiments to precipitate active RhoA protein, both CCL19 and CCL21 activated RhoA within 15 min (Figure 7a ). ROCK is a major downstream target of activated RhoA. 26 To evaluate the ROCK activity, phosphorylated myosin light chain (p-MLC) was measured using western blots. The p-MLC levels increased after 15 min of stimulation with CCL19 or CCL21 (Figure 7b ). To gain further support for the involvement of Rho activation in osteoclast migration, the Rho inhibitors simvastatin and Y27632 were added to the transwell assays. Both Rho inhibitors did not affect BMM viability up to 10 μM (data not shown). The cells treated with Rho inhibitors had a lower migratory response to CCL19 and CCL21 than the cells treated with vehicle (Figure 7c ). When Rho inhibitors were added to the cells cultured on calcium-phosphate plates, the resorption activity of the osteoclasts was significantly suppressed (Figure 7d ). Taken together, these results suggested that the Rho-ROCK signaling pathway mediates the effect of CCL19 and CCL21 on the migration and resorption activities of osteoclasts.
CCL19 and CCL21 increase mouse calvarial bone resorption
To gain evidence for the in vivo effects of CCL19 and CCL21 on bone resorption, we utilized a mouse calvarial model. Chemokine-soaked collagen sheets were transplanted into mouse calvariae, and μ-CT and histomorphometric analyses were performed 7 days after transplantation. CCL19-treated calvariae showed a significantly more resorbed area compared to the PBS-treated calvariae. The PBS-treated group showed 1.79-times more bone volume than that of the CCL19-treated group (Figure 8a ). Histologic analyses revealed that the CCL19-treated group had a greater osteoclast surface/bone surface (Figure 8a ). Since LPS and inflammatory cytokines increased the CCR7 expression, the response to CCL19 or CCL21 might be augmented under inflammatory conditions. To test this possibility, we injected LPS into mice intraperitoneally 1 day before the transplantation of CCL19-soaked collagen. Under these conditions, CCL19 further increased bone resorption and the osteoclast surface/bone surface (Figure 8a ). The bone volume of the PBS-treated group was 2.55 times higher than that of the CCL19-treated group (Figure 8a ). CCL21 also increased resorption in the calvariae: the bone volume of the PBS-treated group was 1.35 times higher than that of the CCL21-treated group and had a greater osteoclast surface/bone surface value (Figure 8b ). An increased osteoclast surface/bone surface was also observed in the CCL21-treated mice (Figure 8b ). These in vivo results provide further evidence for the stimulatory function of CCL19 and CCL21 on osteoclast migration and bone resorption.
DISCUSSION
There is accumulating evidence for an association between the chemokines CCL19 and CCL21 and RA. Using immunohistochemistry, the expression of CCL19 and CCL21 was shown to be higher in synovial tissues from RA patients than in normal tissues. 18 Our analysis of a cDNA microarray data set (GSE1919) revealed higher mRNA levels of CCL19 and CCL21 in RA synovial tissues than in normal synovial tissues (Supplementary Figure 1) , supporting the immunohistochemical results. A previous study using an ELISA to examine the levels of CCL19 and CCL21 in synovial fluids also found increased levels of CCL19 and CCL21 in RA patients compared to those in OA patients. 18 Our experiments confirmed the elevated levels of those cytokines in RA synovial fluids and further detected elevation in the serum (Figure 1 ). In addition, genome-wide association studies have implicated the CCL21 locus as a RA susceptibility gene. 27, 28 These findings suggest the possibility of using CCL19 or CCL21 as biochemical indicators for diagnosing and monitoring the treatment of RA. In support of this proposition, the level of CCL19 in RA patients falls below that of the control level after 1 year of treatment. 19 Some studies suggest that CCR7 is involved in the angiogenesis and migration of leukocytes and lymphocytes to the synovium in RA. [29] [30] [31] Using immunostaining, it was found that the CCR7 protein is more abundant in RA synovial tissues than in normal tissues. 31 In concordance with this report, our analyses of the microarray data set GSE1919 revealed more CCR7 in the synovial tissues from RA patients than in tissues from normal controls (Supplementary Figure 2a) . The results using another data set, GSE10500, showed that among nine CCR family receptors, CCR7 was selectively upregulated on After serum starvation for 6 h, the cells were treated with CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ) for 0, 5, 15 and 30 min. The cells were lysed, and GTP-bound active Rho was pulled down for western blots. A portion of the cell lysate was used to detect the total RhoA protein. (b) BMMs were cultured with M-CSF (30 ng ml − 1 ) for 2 days. After 6 h serum starvation, the cells were stimulated with CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). PMLC in the cell lysates was measured by western blots. β-Actin was used as a loading control. (c) BMMs were pretreated with Rho inhibitors (simvastatin and Y27632) for 1 h and loaded into the upper chambers of a transwell plate. CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ) was added to the bottom chamber. After 16 h, the cells were fixed and stained with crystal violet. (d) BMMs were seeded and cultured with M-CSF (30 ng ml − 1 ) and RANKL (100 ng ml − 1 ) on calcium phosphate-coated plates. After 4 days, the cells were treated with Rho inhibitors (simvastatin and Y27632) in addition to CCL19 (10 ng ml − 1 ) or CCL21 (10 ng ml − 1 ). After 2 days, the cells were removed, and calcium phosphate was stained using the von Kossa method. The resorbed area was quantified. BMM, bone marrow-derived macrophage.
synovial macrophages from RA patients (Supplementary Figure 2b) . Therefore, compared to other CCR types, the CCR7 isoform may have a distinct function as a crucial mediator of RA pathogenesis. In support of this hypothesis, elevated CCR7 on circulating monocytes and T-cells was reduced to baseline by methotrexate treatment in early RA patients. 19 However, the molecular mechanisms and the type of cells that are key elements in the contribution of CCR7 to RA pathogenesis require further investigation.
Monocytes and macrophages are precursor cells that can differentiate into osteoclasts. In our study, CCR7 expression in BMMs was upregulated by treatment with TNF-α, IL-1β and LPS (Figure 2) , while the expression of CCL19 and CCL21 was not detected in BMMs and osteoclasts under challenge or nonchallenge conditions (data not shown). However, inflammatory stimuli increase the CCL19 and CCL21 levels in macrophages and synovial fibroblasts from RA patients. 18 Therefore, TNF-α and IL-1β, which are frequently elevated in RA, may potentiate the recruitment of osteoclast precursor cells to the inflammatory sites of RA via the upregulation of the CCR7 receptor and CCL19/CCL21 ligand pairs. Our experiments with an in vivo calvarial bone lysis model showed more bone loss in response to CCL19 in mice treated with LPS ( Figure 8 ). This result supports a positive in vivo role for CCR7 in the recruitment of osteoclast precursor cells and subsequent bone resorption. Consistently, LPS pretreatment enhanced the stimulatory effects of CCL19 and CCL21 on cell migration and bone resorption in vitro ( Figure 6 ). The osteoclast differentiation factor RANKL alone, without other inflammatory stimuli, had no effect on the CCR7 levels (Figures 2a-c) . This result Figure 8 CCL19 and CCL21 stimulate bone resorption in vivo. (a) Collagen sponges soaked with CCL19 (2 μg) or PBS were transplanted into 5-week-old ICR mouse calvariae. LPS or PBS was injected into the mice intraperitoneally 1 day before and 3 days after transplantation. At 7 days after transplantation, the calvariae were fixed with 4% paraformaldehyde and analyzed by μ-CT. The decalcified calvarial tissue sections were stained for TRAP, and the osteoclast surface/bone surface index was assessed using the Osteomeasure program. (b) Collagen sponges soaked with CCL21 (2 μg) or PBS were transplanted into 5-week-old ICR mouse calvariae. After 7 days, the calvariae were fixed with 4% paraformaldehyde for 1 day and analyzed by μ-CT. The osteoclast surface/bone surface index was determined with decalcified calvarial sections after TRAP-staining using the Osteomeasure program. LPS, lipopolysaccharide; μ-CT, micro-computed tomography.
implies that CCR7 and its ligands have little effect on normal bone remodeling; rather, they have significant impact on bone lysis under inflammatory conditions, such as RA. Therefore, therapeutic strategies targeting CCR7 may have an advantage over other osteoclast-suppressing agents in blocking bone destruction in RA patients.
In spite of extensive studies on the migration-promoting roles of CCL19 and CCL21 in immune responses, 32-37 the effects of CCL19 and CCL21 on osteoclast function have not been studied to date. Other migration-regulating cytokines, such as SDF-1, TGFβ, CX 3 CL1 and macrophage migration inhibitory factor, affect osteoclastogenesis directly or indirectly. [3] [4] [5] 38, 39 Unlike these cytokines, CCL19 and CCL21 had no effect on osteoclast formation; rather, they promoted the migration and resorption activity of BMMs and osteoclasts ( Figures 3,4,5 ). In the in vivo calvarial model, the CCL19-and CCL21-treated groups showed higher osteoclast surface/bone surface values than the control groups ( Figure 8 ). This in vivo result of seemingly increased osteoclastogenesis is likely to be due to the stimulatory effect of the cytokines on the migration of osteoclast precursor cells rather than an effect on differentiation per se. The migration and resorption responses involve actin cytoskeletal events. The activation of the small GTPase RhoA is a critical step in actin cytoskeleton reorganization. Previous studies have shown that RhoA is responsible for osteoclast motility, 24 podosome organization, 40 actin ring and sealing zone formation, 41 and bone resorption. 24 Downstream of RhoA, ROCK activates WASP, myosin light chain and ERM proteins, 42, 43 which are implicated in bone resorption. 44, 45 In this study, we found that the stimulation of osteoclast migration, actin ring formation and bone resorption by CCL19 and CCL21 was mediated by the Rho-ROCK pathway.
In summary, we found that the levels of the chemokines CCL19 and CCL21 were elevated in the blood and synovial fluids of RA patients. The expression of the CCL19 and CCL21 receptor CCR7 was also markedly increased in the synovial tissues of RA patients. In addition, CCR7 was upregulated in osteoclasts by inflammatory stimuli. CCL19 and CCL21 stimulated osteoclast migration and resorption activity via the CCR7/Rho signaling pathway. Our findings support the CCL19/CCL21-CCR7 interaction as a novel focus in the development of RA therapeutics. Neutralizing antibodies for the chemokines and CCR7-reducing strategies involving CCR7 monoclonal antibodies, 46 histone H3K27me3 methylation, 47 and miRNA 7a and miRNA 21 48, 49 may be explored to reduce both lymphocyte infiltration and osteoclastic bone resorption to effectively alleviate RA progression.
